Mode
Text Size
Log in / Sign up
N/A Completed N=248 Randomized Treatment

Investigation to Evaluate the Efficacy and Safety of Exufiber Versus Aquacel Extra in Moderately or Strongly Exuding Venous and Mixed Ulcers of Predominantly Venous Origin

Source: ClinicalTrials.gov NCT02921750 ↗
Enrolled (actual)
248
Serious AEs
5.2%
Results posted
Nov 2020
Primary outcomePrimary: Wound Area Change (%) — -49.7; -42.4 relative wound area change in percentage — p=0.093

Summary

The investigation is designed as an open, randomized, non-inferiority, multi-centre investigation. 212 evaluable subjects will be randomised. Subjects to be included will suffer from an exuding venous or mixed ulcer of predominantly venous origin. Subjects will either be randomized to Exufiber®Gelling Fibre Dressing or Aquacel®Extra Hydrofiber® Dressing with Strengthening Fibre using, centralized randomization

Outcome Measures

OutcomeResultp-value
PRIMARY
Wound Area Change (%)
-49.7; -42.4 0.093
SECONDARY
Wound Area Change (cm2)
-4.64; -3.48
SECONDARY
Linear Advance of Wound Margin
0.008; 0.007
SECONDARY
Pain During Debridement
25.8; 26.9
SECONDARY
Pain at Dressing Removal
16.3; 16.9
SECONDARY
Percentage of Clinicians of Opinion 'Very Good' for Dressing Features
58.4; 57.5; 48.7; 35.9; 48.0; 40.8
SECONDARY
Percentage of Clinicians of Opinion 'Does Not Adhere' Related to Dressing Features
44.2; 31.1; 72.0; 52.1

Eligibility Criteria

Inclusion Criteria

  • Provision of informed consent i.e. subject must be able to understand and sign the Patient Information and Consent Form
  • Both gender ≥18 years old
  • Ulcer moderately or strongly exudative justifying the use of an absorbent dressing
  • (History of compression at least two weeks before inclusion) Deleted in Am.2
  • (Wound covered with slough ≥70%) Deleted in Am.4
  • 0.7≤ABPI<1.3
  • Ulcer duration 6 weeks to 60 months
  • Ulcer size 3 cm2-100 cm2
  • Target ulcer at least 3 cm away from any other lesion

Exclusion Criteria

  • Known allergy/hypersensitivity to the dressings
  • Pregnant or breastfeeding
  • Circumferential wounds (the entire wound should be able to be captured on a single image/photo)
  • Subjects who will have problems following the protocol
  • Subjects included in other ongoing clinical investigation evaluating wound dressings at present or during the past 30 days
  • Patient with a systemic infection not controlled by suitable antibiotic treatment
  • Clinically infected wound according to the judgement of the investigator (heat, pain, swelling, redness or purulent secretion)
  • Wound covered with black necrosis
  • Dry wounds
  • Malignant wound degeneration
  • Current treatment with radiotherapy, chemotherapy, immunosuppressant drugs or high doses of oral corticosteroids if any
  • Subject with deep vein thrombosis within 3 months prior to inclusion
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02921750). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search